- Home
- BHC vs VCEL Comparison
BHC vs VCEL Comparison
Compare BHC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHC | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BHC | VCEL |
|---|---|---|
| Price | $5.81 | $40.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.0M | 442.3K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | $276,259,000.00 |
| Revenue This Year | $4.61 | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $4.33 | $28.95 |
| 52 Week High | $8.00 | $49.32 |
Technical Indicators
Market Signals| Indicator | BHC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 41.83 |
| Support Level | $5.42 | $35.32 |
| Resistance Level | $5.96 | $41.25 |
| Average True Range (ATR) | 0.24 | 1.13 |
| MACD | -0.10 | 0.17 |
| Stochastic Oscillator | 9.76 | 57.25 |
Price Performance
Historical ComparisonAbout BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.